Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shihchen Kuo

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|February 7, 2020
Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected populationChun-Ting Yang, Han-Siong Toh, Chia-Te Liao, et al.
Cardiovascular Diabetology|July 10, 2024
Longitudinal economic burden of incident complications among metabolic syndrome populationsKah Suan Chong, Yi-Hsin Chang, Chun-Ting Yang, et al.
Diabetes Research and Clinical Practice|June 18, 2025
Economic burdens of type 1 diabetes and its complications: A nationwide, longitudinal analysisKah Suan Chong, Yu-Hsuan Lee, Yi-Hsin Chang, et al.
Journal of Diabetes Science and Technology|July 5, 2011
Cost-effectiveness of implementing the chronic care model for diabetes care in a military populationShihchen Kuo, Cindy L Bryce, Janice C Zgibor, et al.
BMC Nutrition|October 15, 2025
Can a vegan diet help people with type 1 diabetes save on insulin? A secondary analysis of a 12-Week randomized clinical trialHana Kahleova, Cristina Maracine, Tatiana Znayenko-Miller, et al.
JAMA Network Open|December 15, 2022
Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in TaiwanZi-Yang Peng, Chun-Ting Yang, Shihchen Kuo, et al.
Cardiovascular Diabetology|October 18, 2024
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control studyKai-Cheng Chang, Fan-Chi Kuo, Chen-Yi Yang, et al.
Journal of Internal Medicine|November 23, 2023
Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation frameworkChun-Ting Yang, Wen-Yu Yao, Chen-Yi Yang, et al.
Cardiovascular Diabetology|October 4, 2023
Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort studyZi-Yang Peng, Chun-Ting Yang, Wei-Hung Lin, et al.
Preventive Medicine|February 28, 2016
Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular riskKenneth J Smith, Shihchen Kuo, Janice C Zgibor, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|February 7, 2020
Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected populationChun-Ting Yang, Han-Siong Toh, Chia-Te Liao, et al.
Cardiovascular Diabetology|July 10, 2024
Longitudinal economic burden of incident complications among metabolic syndrome populationsKah Suan Chong, Yi-Hsin Chang, Chun-Ting Yang, et al.
Diabetes Research and Clinical Practice|June 18, 2025
Economic burdens of type 1 diabetes and its complications: A nationwide, longitudinal analysisKah Suan Chong, Yu-Hsuan Lee, Yi-Hsin Chang, et al.
Journal of Diabetes Science and Technology|July 5, 2011
Cost-effectiveness of implementing the chronic care model for diabetes care in a military populationShihchen Kuo, Cindy L Bryce, Janice C Zgibor, et al.
BMC Nutrition|October 15, 2025
Can a vegan diet help people with type 1 diabetes save on insulin? A secondary analysis of a 12-Week randomized clinical trialHana Kahleova, Cristina Maracine, Tatiana Znayenko-Miller, et al.
JAMA Network Open|December 15, 2022
Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in TaiwanZi-Yang Peng, Chun-Ting Yang, Shihchen Kuo, et al.
Cardiovascular Diabetology|October 18, 2024
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control studyKai-Cheng Chang, Fan-Chi Kuo, Chen-Yi Yang, et al.
Journal of Internal Medicine|November 23, 2023
Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation frameworkChun-Ting Yang, Wen-Yu Yao, Chen-Yi Yang, et al.
Cardiovascular Diabetology|October 4, 2023
Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort studyZi-Yang Peng, Chun-Ting Yang, Wei-Hung Lin, et al.
Preventive Medicine|February 28, 2016
Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular riskKenneth J Smith, Shihchen Kuo, Janice C Zgibor, et al.
Pageof 7